Recruiting

Costotransverse Foramen Block vs Thoracic Paravertebral Block in Thoracotomy Pain Management

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Costotransverse foramen block

+ Thoracic paravertebral plane block

Other
Who is being recruted

Lung Diseases+4

+ Lung Neoplasms

+ Neoplasms

From 18 to 65 Years
+12 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: January 2026
See protocol details

Summary

Principal SponsorNational Cancer Institute, Egypt
Study ContactMai M Elrawas, MD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 24, 2026

Actual date on which the first participant was enrolled.

Thoracotomy, a type of surgery for lung cancer, is known to be one of the most painful procedures. Around 75% of patients experience moderate to severe pain after the surgery. To manage this pain, doctors use various techniques such as thoracic epidural analgesia (TEA), thoracic paravertebral block (TPVB), and erector spinae plane block (ESPB). TEA, once considered the best method, has side effects that prompted researchers to explore other options. One such alternative is the costotransverse foramen block (CTFB), a recently introduced technique that has shown promise in both cadaveric and case studies. This study aims to find a safer and more effective method to manage post-thoracotomy pain. During the study, participants will receive either a CTFB or a TPVB. If a patient's pain level, measured on a visual analog scale (VAS), reaches 4 or higher, they will be given a 4 mg bolus of morphine as a rescue analgesic. The study's primary outcome is to measure the total amount of morphine consumed by each patient. This will help determine which technique, CTFB or TPVB, is more effective in managing pain after thoracotomy.

Official TitleCostotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer: A Randomized Controlled Trial
Principal SponsorNational Cancer Institute, Egypt
Study ContactMai M Elrawas, MD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

70 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Lung DiseasesLung NeoplasmsNeoplasmsNeoplasms by SiteRespiratory Tract DiseasesRespiratory Tract NeoplasmsThoracic Neoplasms

Criteria

4 inclusion criteria required to participate
Age > 18 years and ≤ 65 years old.

American Society of Anesthesiologists (ASA) physical status II-III.

Body mass index 18-35 kg/m2.

Patients scheduled for thoracotomies for lung cancer.

8 exclusion criteria prevent from participating
Patient refusal.

History of sensitivity to local anesthetics.

History of psychological disorders.

Contraindication to regional anesthesia, e.g., local sepsis, pre-existing peripheral neuropathies, and coagulopathy.

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Patients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%.

Group II

Experimental
Patients will receive an ipsilateral ultrasound-guided thoracic paravertebral plane block with injection of 20 ml bupivacaine 0.25%.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Cairo University

Cairo, EgyptOpen Cairo University in Google Maps
Recruiting
One Study Center